In a review of 32 randomized trials with 47,332 participants, tirzepatide was associated with fewer hypertension-related adverse events and more hypotension-related adverse events than the comparators [1]. The NHANES blood pressure analysis used a different approach and included only 45 people who reported using a GLP-1 drug. The trial review counted reported events, while the survey analysis examined blood pressure measurements.
A separate analysis of three SURMOUNT outcomes evaluated weight, measured blood pressure and non-HDL cholesterol together. Across trials, 22% to 34% of tirzepatide participants and 1% to 3% of placebo participants met all three targets when the weight-loss threshold was at least 15% [2].
What was counted
The meta-analysis included 32 randomized trials with 47,332 participants treated for type 2 diabetes or obesity [1]. It pooled reports of hypertension- and hypotension-related events that occurred during treatment.
The trade
Tirzepatide was associated with a lower risk of hypertension-related events, RR 0.40, 95% CI 0.26 to 0.60, p<0.001. That is a large reduction and it is the kind of finding that gets quoted alone.
It was also associated with more hypotension-related events, RR 2.45, 95% CI 1.35 to 4.45, p=0.003. At higher doses that rose to RR 2.58, 95% CI 1.38 to 4.81. The review counted reported adverse events and did not estimate the amount by which blood pressure changed.
What the review found for semaglutide
For semaglutide the hypertension-related risk ratio was 0.81, 95% CI 0.57 to 1.15, and the hypotension-related risk ratio 1.39, 95% CI 0.81 to 2.36. Both intervals include no effect, so the analysis did not establish a difference for either event category.
Comparing prices for a prescription
Across 142 sellers publishing prices for both injections, tirzepatide costs a median of $70 more per month. The price check helps compare quotes for the medication you were prescribed. The latest price check on record was November 2026. The trial review did not test whether paying more changes your individual risk.
The GLP-1 side-effects guide covers additional outcomes that belong in a discussion with your prescriber. This review examined only blood-pressure-related events.
What the design cannot tell you
How big any of this is in absolute terms. Risk ratios describe proportional change and the abstract gives no event rates. So a reader cannot tell whether a 2.45-fold increase means a rare thing became less rare, or a common thing became commoner. Without those numbers the practical size of the trade is unknown.
And adverse-event capture varies between trials — what one study records as a hypotension-related event another may not record at all. Pooling 32 trials averages over that inconsistency rather than resolving it.